Cargando…

Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography

BACKGROUND: Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in foveal avascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ziyi, Liang, Youling, Yan, Bin, Meng, Zhishang, Long, Kejun, Zhang, Yiwei, Luo, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519504/
https://www.ncbi.nlm.nih.gov/pubmed/32977791
http://dx.doi.org/10.1186/s12886-020-01648-x
_version_ 1783587584195166208
author Zhu, Ziyi
Liang, Youling
Yan, Bin
Meng, Zhishang
Long, Kejun
Zhang, Yiwei
Luo, Jing
author_facet Zhu, Ziyi
Liang, Youling
Yan, Bin
Meng, Zhishang
Long, Kejun
Zhang, Yiwei
Luo, Jing
author_sort Zhu, Ziyi
collection PubMed
description BACKGROUND: Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in foveal avascular zone (FAZ) areas and capillary density in macular regions by applying optical coherence tomography angiography (OCTA). METHODS: Fifty patients were divided into ischemic (n = 31) and non-ischemic (n = 19) groups according to the presence of ischemia on OCTA at baseline. All patients received intravitreal injections of 0.5 mg of conbercept with 3+ PRN principle. The FAZ areas and macular vessel density measured using OCTA were evaluated at baseline, 3 months, and 6 months after treatment in both groups. RESULTS: At months 3 and 6, the FAZ area in the ischemic group changed from 0.510 ± 0.171 mm(2) to 0.441 ± 0.158 mm(2) then to 0.427 ± 0.153 mm(2) (p = 0.003, p = 0.296); in the non-ischemic group, it remained stable (p = 0.269, p = 0.926). The superficial vessel density changed from 41.1 ± 4.1 to 42.5% ± 4.7% then to 42.6% ± 4.6% (p = 0.043, p = 0.812), and the deep vessel density changed from 40.7 ± 4.4 to 42.3% ± 3.6% then to 42.3% ± 4.7% (p = 0.072, p = 0.961) in the ischemic group. In the non-ischemic group, the superficial vessel density changed from 44.8 ± 3.2 to 46.0% ± 3.5% then to 45.7% ± 3.3% (p = 0.108, p = 0.666), whereas the deep vessel density changed from 43.6 ± 3.6 to 43.8% ± 3.2% then to 43.5% ± 4.5% (p = 0.882, p = 0.736). Reperfusion in macular nonperfusion areas was observed. CONCLUSION: Anti–vascular endothelial growth factor treatment may have a positive effect on macular perfusion status. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status.
format Online
Article
Text
id pubmed-7519504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75195042020-09-29 Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography Zhu, Ziyi Liang, Youling Yan, Bin Meng, Zhishang Long, Kejun Zhang, Yiwei Luo, Jing BMC Ophthalmol Research Article BACKGROUND: Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in foveal avascular zone (FAZ) areas and capillary density in macular regions by applying optical coherence tomography angiography (OCTA). METHODS: Fifty patients were divided into ischemic (n = 31) and non-ischemic (n = 19) groups according to the presence of ischemia on OCTA at baseline. All patients received intravitreal injections of 0.5 mg of conbercept with 3+ PRN principle. The FAZ areas and macular vessel density measured using OCTA were evaluated at baseline, 3 months, and 6 months after treatment in both groups. RESULTS: At months 3 and 6, the FAZ area in the ischemic group changed from 0.510 ± 0.171 mm(2) to 0.441 ± 0.158 mm(2) then to 0.427 ± 0.153 mm(2) (p = 0.003, p = 0.296); in the non-ischemic group, it remained stable (p = 0.269, p = 0.926). The superficial vessel density changed from 41.1 ± 4.1 to 42.5% ± 4.7% then to 42.6% ± 4.6% (p = 0.043, p = 0.812), and the deep vessel density changed from 40.7 ± 4.4 to 42.3% ± 3.6% then to 42.3% ± 4.7% (p = 0.072, p = 0.961) in the ischemic group. In the non-ischemic group, the superficial vessel density changed from 44.8 ± 3.2 to 46.0% ± 3.5% then to 45.7% ± 3.3% (p = 0.108, p = 0.666), whereas the deep vessel density changed from 43.6 ± 3.6 to 43.8% ± 3.2% then to 43.5% ± 4.5% (p = 0.882, p = 0.736). Reperfusion in macular nonperfusion areas was observed. CONCLUSION: Anti–vascular endothelial growth factor treatment may have a positive effect on macular perfusion status. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status. BioMed Central 2020-09-25 /pmc/articles/PMC7519504/ /pubmed/32977791 http://dx.doi.org/10.1186/s12886-020-01648-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhu, Ziyi
Liang, Youling
Yan, Bin
Meng, Zhishang
Long, Kejun
Zhang, Yiwei
Luo, Jing
Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title_full Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title_fullStr Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title_full_unstemmed Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title_short Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
title_sort clinical effect of conbercept on improving diabetic macular ischemia by oct angiography
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519504/
https://www.ncbi.nlm.nih.gov/pubmed/32977791
http://dx.doi.org/10.1186/s12886-020-01648-x
work_keys_str_mv AT zhuziyi clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT liangyouling clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT yanbin clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT mengzhishang clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT longkejun clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT zhangyiwei clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography
AT luojing clinicaleffectofconberceptonimprovingdiabeticmacularischemiabyoctangiography